UroGen Pharma Ltd., a Princeton-based biotechnology company, is on a mission to develop innovative solutions for specialty cancers and urothelial diseases. Their product offerings include RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel that enhances existing drug therapies, and Jelmyto, a pyelocalyceal solution. The company's lead product candidate, UGN-102, aims to treat multiple forms of non-muscle invasive urothelial cancer such as low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Another promising product in development is UGN-301, which targets high-grade non-muscle invasive bladder cancer. In collaboration with Agenus Inc., UroGen plans to develop, manufacture, use, sell, import, and commercialize products for the treatment of urinary tract cancers via intravesical delivery. They also have a strategic research partnership with MD Anderson focused on advancing investigational treatments for NMIBC. Founded in 2004, UroGen Pharma Ltd. is an emerging player in the biotech industry, dedicated to introducing groundbreaking therapies for urological diseases and cancers.
UroGen Pharma Ltd.'s ticker is URGN
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at UroGen Pharma Ltd.
It is https://www.urogen.com/
UroGen Pharma Ltd. is in the Healthcare sector
UroGen Pharma Ltd. is in the Biotechnology industry
The following five companies are UroGen Pharma Ltd.'s industry peers: